Legal Status Overview
Gray AreaPeptides are not addressed by any Wyoming-specific statute, administrative code, or Board of Pharmacy rule; Wyoming has no law naming 'peptides' or 'research chemicals' as a distinct legal category. Instead, Wyoming compounding pharmacies operate under the state Pharmacy Act's adoption of the federal 503A/503B framework, meaning a peptide's legality in Wyoming depends on its current FDA bulk-drug-substance classification, which for compounds like BPC-157 and TB-500 has been in active flux through 2026. GLP-1 drugs (semaglutide, tirzepatide) are FDA-approved brand-name prescription drugs, so compounded copies of them are legal only under narrow circumstances such as drug shortages or patient-specific need. No Wyoming legislative bill or attorney general guidance specific to peptides or research chemicals was found in the last several legislative sessions.
Key Points
- Wyoming has no statute, administrative rule, or Board of Pharmacy regulation that names 'peptides' or 'research chemicals' as a distinct legal category, based on a review of the Wyoming Pharmacy Act rules and Board of Pharmacy controlled-substance chapter. [7]
- No Wyoming legislative bill specific to peptides, research chemicals, or compounded GLP-1 drugs was found in the 2024 or 2025 Wyoming legislative sessions tracked by LegiScan. [8]
- The Wyoming State Board of Pharmacy regulates compounding pharmacies and outsourcing facilities under Wyoming Pharmacy Act Rules Chapter 8, which explicitly incorporates the federal '503(b)' outsourcing-facility framework rather than creating a separate Wyoming peptide standard. [3]
- The FDA classified BPC-157 as a Category 2 bulk drug substance with significant safety concerns in 2023, which barred 503A compounding pharmacies (including those in Wyoming) from legally compounding it, before FDA removed BPC-157 from Category 2 on April 15, 2026. [4]
- In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, TB-500, MOTS-c, KPV, and Semax to the 503A Bulks List, but this is only a recommendation to FDA and does not itself make these peptides legal to compound in Wyoming or any other state until FDA finalizes the listing. [6]
- Semaglutide and tirzepatide are FDA-approved brand-name prescription drugs (marketed as Ozempic/Wegovy and Mounjaro/Zepbound), so a Wyoming pharmacy can only legally compound versions of them under narrow exceptions such as an FDA-declared drug shortage or a patient-specific medical need, not as routine alternatives to the branded product. [5]
- A person cannot legally buy or bring peptide drugs like BPC-157, TB-500, or compounded semaglutide into Wyoming for personal human use without a valid prescription from a licensed prescriber filled through a state-licensed or 503A/503B-compliant pharmacy; products marketed online as 'research use only' are not legal for human consumption regardless of how they are labeled. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
- Wyoming compounding pharmacists must meet Board-recognized sterile compounding proficiency standards, such as the Board Certified Sterile Compounding Pharmacist (BCSCP) program the Wyoming State Board of Pharmacy approved as qualifying certification in March 2026 for outsourcing facilities. [3]
Peptide-by-peptide status in Wyoming
| BPC-157 | BPC-157 has no Wyoming-specific ban but sits in federal regulatory limbo: FDA had barred it from 503A compounding as a Category 2 safety-concern substance, removed that restriction in April 2026, and in July 2026 an FDA advisory panel recommended (but has not finalized) adding it to the approved 503A Bulks List, so it remains an unapproved, non-FDA-approved peptide with an uncertain compounding pathway in Wyoming as elsewhere. [4] |
|---|---|
| Semaglutide / Tirzepatide (GLP-1 class) | Semaglutide and tirzepatide are legal in Wyoming only as FDA-approved, prescription-only brand-name drugs (e.g., Ozempic, Wegovy, Mounjaro, Zepbound), with compounded versions permitted just under narrow federal exceptions like declared drug shortages rather than as a routine legal alternative. [5] |
| TB-500 | TB-500 has no Wyoming-specific legal status of its own and, like BPC-157, is an unapproved peptide that an FDA advisory committee recommended in July 2026 for the 503A Bulks List without that recommendation yet being finalized into a rule that would make it lawfully compoundable. [6] |
| HGH / somatropin (growth hormone peptides) | Human growth hormone products are prescription-only drugs under federal law with no Wyoming-specific statute located addressing them separately, so their lawful use in Wyoming depends on a valid prescription for an FDA-approved indication rather than any state peptide rule. |
Sources
Last researched: 2026-09-09
Frequently asked questions
Can I buy peptides in Wyoming without a prescription?
No — peptides intended for human use, including BPC-157, TB-500, and GLP-1 drugs, cannot be legally sold for human consumption in Wyoming without a valid prescription, and products marketed as 'research use only' are not a legal workaround for personal use. [1]
Does Wyoming have its own peptide law separate from federal rules?
No — Wyoming has no peptide-specific statute or Board of Pharmacy rule; peptide legality in Wyoming is governed entirely by the state's general Pharmacy Act compounding rules layered on top of the federal FDA 503A/503B framework. [7]
Is BPC-157 legal to buy in Wyoming right now?
BPC-157's status is unsettled everywhere including Wyoming: FDA lifted its 2023 Category 2 safety-concern restriction on BPC-157 in April 2026, and an FDA advisory panel recommended it for the 503A compounding list in July 2026, but that recommendation had not been finalized as of the most recent reporting, so it remains an unapproved compound rather than a clearly legal one. [4]
Can a telehealth provider legally prescribe peptides to someone in Wyoming?
No Wyoming-specific telehealth rule for peptides was found in this research; any prescribing would need to follow Wyoming's general telehealth and prescribing rules plus the same federal FDA-approval/compounding limits that apply to in-person prescribing.
What happens if I get caught selling unapproved peptides in Wyoming?
No Wyoming-specific enforcement action or penalty schedule targeting peptide sellers was identified in this research, so any enforcement would likely proceed under the state's general Pharmacy Act and controlled-substance provisions or through FDA/DOJ action rather than a peptide-specific Wyoming penalty.